These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36790032)

  • 1. Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study.
    Xu MH; Huang C; Li ML; Zhu XD; Tan CJ; Zhou J; Fan J; Sun HC; Shen YH
    Cancer Med; 2023 Apr; 12(8):9202-9212. PubMed ID: 36790032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.
    Wu CJ; Lee PC; Hung YW; Lee CJ; Chi CT; Lee IC; Hou MC; Huang YH
    Cancer Immunol Immunother; 2022 Nov; 71(11):2631-2643. PubMed ID: 35347395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma.
    Su CW; Teng W; Lin PT; Jeng WJ; Chen KA; Hsieh YC; Chen WT; Ho MM; Hsieh CH; Wang CT; Chai PM; Lin CC; Lin CY; Lin SM
    Cancer Med; 2023 Mar; 12(6):7077-7089. PubMed ID: 36468578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of anti-PD-1 monotherapy
    Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
    Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study.
    Ding Z; Fang G; Tang Y; Zeng Y
    Sci Rep; 2024 Jun; 14(1):14334. PubMed ID: 38906915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
    Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients.
    Zou J; Huang P; Ge N; Xu X; Wang Y; Zhang L; Chen Y
    J Gastrointest Oncol; 2022 Aug; 13(4):1898-1906. PubMed ID: 36092355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma.
    Enomoto D; Yamamoto K; Matsumoto Y; Morioka A; Omura T; Komatsu S; Yano Y; Fukumoto T; Yano I
    Anticancer Res; 2023 Mar; 43(3):1317-1323. PubMed ID: 36854508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.
    Tsuchiya K; Kurosaki M; Sakamoto A; Marusawa H; Kojima Y; Hasebe C; Arai H; Joko K; Kondo M; Tsuji K; Sohda T; Kimura H; Ogawa C; Uchida Y; Wada S; Kobashi H; Furuta K; Shigeno M; Kusakabe A; Akahane T; Narita R; Yoshida H; Mitsuda A; Ide Y; Matsushita T; Izumi N; On Behalf Of Japanese Red Cross Liver Study Group
    Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
    Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
    World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
    Rimini M; Persano M; Tada T; Suda G; Shimose S; Kudo M; Cheon J; Finkelmeier F; Lim HY; Presa J; Salani F; Lonardi S; Piscaglia F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Schirripa M; Montes M; Vivaldi C; Soldà C; Hiraoka A; Sho T; Niizeki T; Nishida N; Steup C; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Burgio V; Scartozzi M; Cascinu S; Casadei-Gardini A
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7565-7577. PubMed ID: 36976353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma.
    Xin Y; Zhang X; Liu N; Peng G; Huang X; Cao X; Zhou X; Li X
    Hepatol Int; 2023 Jun; 17(3):753-764. PubMed ID: 37038024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Matono T; Kuroda H; Yata Y; Ohama H; Tada F; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Yokohama K; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; ;
    Oncology; 2023; 101(10):624-633. PubMed ID: 37307798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma.
    Lee PC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lee MH; Hou MC; Lee FY; Lin HC; Huang YH
    Liver Int; 2018 Feb; 38(2):321-330. PubMed ID: 28736952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Zou X; Xu Q; You R; Yin G
    Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma.
    Hiraoka A; Kumada T; Tada T; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Toyoda H; Ohama H; Tsutsui A; Itokawa N; Hayama K; Arai T; Imai M; Nakamura S; Michitaka K; Hiasa Y; Kudo M;
    Oncology; 2020; 98(5):295-302. PubMed ID: 32097925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.
    Sun X; Zhang Q; Mei J; Yang Z; Chen M; Liang T
    BMC Cancer; 2022 Mar; 22(1):293. PubMed ID: 35305593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study.
    Chen J; Xiong P; Nie M; Pan Y; Wang J; Hu D; Zhou Z; Zhang Y; Chen M; Xu L
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2491-2500. PubMed ID: 35752744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation.
    Bang K; Casadei-Gardini A; Yoo C; Iavarone M; Ryu MH; Park SR; Kim HD; Yoon YI; Jung DH; Park GC; Ahn CS; Moon DB; Hwang S; Kim KH; Song GW; Mazzarelli C; Alimenti E; Chan SL; De Giorgio M; Ryoo BY; Lee SG
    Cancer Med; 2023 Feb; 12(3):2572-2579. PubMed ID: 36812124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
    Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
    World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.